Given recent studies showing the imbalances in the effector and regulatory Tfh cell compartment in SLE patients [3, 4], and in light of our finding that low-dose IL-2 treatment significantly influences Tfh subtypes, we recruited a small cohort of healthy controls (HC) (n=23, Table 1) for comparative analysis. The gene discussed is IL2; the disease is systemic lupus erythematosus.